— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.
— Total revenues were $295.6 million, vs. $283 million expected.
— Screening revenues increased 60% to $229.4 million.
— Cologuard test volume rose 63% to 477,000.
— Average Cologuard recognized revenue per test was $481.
— Average Cologuard cost per test was $123.
— Precision Oncology proforma revenue increased 14% to $119.1 million.
— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.
— FY2020 Screening revenue is expected to be $1.125-1.15 billion.
— FY2020 Precision Oncology revenue is expected to be $485-495 million.
— EXAS shares gained 1.2% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.